ARA-290 (Cibinetide): Evidence, Mechanism & Legal Status

ARA-290 (cibinetide; also called pHBSP or helix B surface peptide) is an 11-amino-acid peptide engineered from erythropoietin and developed for tissue protection and nerve repair — most credibly for small-fiber neuropathy.1 Unlike most peptides circulating in recovery and longevity circles, it carries real Phase 2 trial data. This monograph separates what is proven from what is hyped.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. ARA-290 is not an FDA-approved drug; it is sold as a "research chemical not for human use" and is prohibited in sport. Dosing figures are reported strictly as seen in the published literature and registered trials for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is ARA-290 and how does it work?

ARA-290/cibinetide is a synthetic 11-amino-acid linear peptide (sequence pyroGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser; molecular formula C51H84N16O21, MW about 1257 Da, CAS 1208243-50-8) corresponding to the aqueous-exposed face of helix B of erythropoietin.16 It was designed by Michael Brines and Anthony Cerami at Araim Pharmaceuticals.2

The mechanism is the most elegant part of the story. Erythropoietin signals through two distinct receptor systems: the classical homodimeric EPO receptor on erythroid progenitors that drives red-cell production, and the innate repair receptor (IRR) — a heterocomplex of the EPO receptor subunit with the beta-common receptor (CD131, the shared signaling chain of the GM-CSF, IL-3 and IL-5 receptors). ARA-290 binds the IRR with high selectivity and has negligible activity at the erythropoietic receptor, which is the mechanistic basis for its "non-erythropoietic" profile.12 Because the IRR is locally upregulated under injury, hypoxia, inflammation or metabolic stress, ARA-290 behaves as a context-restricted agonist — activating repair preferentially where the receptor is induced. Engagement triggers JAK2 phosphorylation with downstream STAT3 and PI3K-Akt signaling, upregulation of anti-apoptotic Bcl-2-family proteins, and suppression of pro-inflammatory cytokines such as TNF-alpha and IL-6, with documented modulation of macrophage and spinal microglial responses in injury models.5

Pharmacokinetically it is a peptide, not orally bioavailable, given by injection. Its plasma half-life is very short — terminal t-half of roughly 20 minutes after a 4 mg subcutaneous dose — yet a core feature is the dissociation between plasma exposure and biological duration: the peptide acts like a molecular switch, producing effects that persist far longer than its minutes-long circulating life through the downstream signaling cascade.12

What is the evidence by indication?

Human Phase 2 RCT evidence is real but limited: small samples, largely from a single Leiden/Araim research network, never advanced to Phase 3, no approval. The lead indications earn Grade B; the broader claims rest on animal data only (Grade C). The completed pivotal trial is registered at ClinicalTrials.gov (NCT02039687), with results posted.4

The sarcoidosis program is the best-evidenced and the basis for orphan designation. A single-site pilot RCT (n=22 completers; 2 mg IV thrice weekly for four weeks) showed significantly greater improvement on the Small Fiber Neuropathy Screening List versus placebo (p < 0.05) and significant within-group gains in SF-36 pain and physical functioning — though Brief Pain Inventory and fatigue improved similarly in both arms, tempering the pain-specific claim, with no erythropoietic effect.1 The pivotal Phase 2b dose-ranging RCT (n=64; 1, 4 or 8 mg SC daily for 28 days) was the program's strongest result: placebo-corrected corneal nerve fiber area increased significantly only in the 4 mg group (+697 micrometers-squared; 95% CI 159-1236; P = 0.012) — roughly a 23% rise in corneal nerve abundance — while skin GAP-43-positive regenerating intraepidermal fibers also increased (P = 0.035), and the two anatomic measures correlated with each other and with the six-minute walk test.3 That is concordant, objective, blinded evidence of nerve regeneration across two tissues. The catch: pain improved across all groups and the placebo-corrected pain reduction did not reach significance (P = 0.157).3

In type 2 diabetic neuropathy, a double-blind, placebo-controlled RCT (n=48; 4 mg SC daily for 28 days) showed significant improvement in HbA1c (p = 0.002), cholesterol/HDL ratio (p = 0.039) and triglycerides (p = 0.043), plus neuropathic-symptom improvement on PainDetect. Full-cohort corneal nerve fiber density change was non-significant, but in the prespecified subgroup with baseline density more than 1 SD below normal, ARA-290 increased nerve fiber density (p = 0.02). There was no erythropoietic effect and anti-drug antibodies were negative — though the absolute HbA1c change was small, about 0.2%.2

What doses appear in the literature?

Reported strictly as information, not a protocol. The most-studied regimen is 4 mg subcutaneous, self-administered once daily, for 28 days — the dose that hit objective endpoints in both the pivotal sarcoidosis Phase 2b and the diabetes RCT.23 The pivotal trial tested 1, 4 and 8 mg subcutaneous daily; efficacy followed an inverted-U curve, with 4 mg optimal and 8 mg no better — and on the primary endpoint, non-significant — so more was not better.3 The earlier IV pilot used 2 mg intravenously in saline over about two minutes, thrice weekly for four weeks.1 Trial material was a sterile peptide solution prepared for parenteral injection; no FDA-approved formulation, labeled concentration or sanctioned compounding pathway exists, and products sold online are unregulated and of unverified identity and purity.111

How safe is ARA-290?

Across the Phase 2 program, cibinetide was generally well tolerated. The IV pilot reported no adverse events.1 In the diabetes RCT, adverse-event frequency was similar to placebo and predominantly mild; there were four serious adverse events in the active arm, of which two were judged possibly related (worsening borderline renal insufficiency in a patient on furosemide, prompting a stop; and a fatal myocardial infarction in a 70-year-old two weeks after the last dose, judged unrelated).2 Commonly cited mild effects with subcutaneous dosing are injection-site reactions and transient headache.12 A central design feature is hematologic safety: repeated dosing produced no change in hemoglobin or hematocrit in either trial, confirming the non-erythropoietic profile and, by design, avoiding EPO's thrombosis, hypertension and viscosity risks.12

The theoretical risks are mechanistic. As an EPO-pathway agonist that promotes angiogenesis and anti-apoptotic signaling in repair models, ARA-290 raises a precautionary concern about supporting tumor angiogenesis, so caution is warranted in active malignancy — though no human tumor-promotion signal has been demonstrated.13 Repeated dosing of a synthetic peptide can elicit anti-drug antibodies; the diabetes trial measured these and found them negative at day 28, but longer-term immunogenicity is unestablished.2 Long-term safety beyond four-to-eight-week exposures is simply not characterized. Precautionary or contraindicated populations include pregnancy or lactation, active or suspected malignancy, severe renal impairment, and athletes subject to anti-doping testing; trials excluded BMI above 34 and capped age around 65-70.12

What is the FDA and WADA status in 2026?

ARA-290/cibinetide is not FDA-approved for any indication and remains investigational. It holds FDA Orphan Drug Designation for sarcoidosis (granted July 5, 2016) and a separate Orphan Drug plus Fast Track designation for neuropathic pain in sarcoidosis.79 Critically, orphan and Fast Track designations support development — seven-year exclusivity, fee waivers, expedited review channels — but they are not marketing approval. No NDA or BLA was filed; the developer, Araim Pharmaceuticals, reportedly ceased operations, and there is no active sponsor IND, leaving no legal compounding pathway and no licensed prescriber access in the US.1214 The EMA granted orphan designation for sarcoidosis and, separately, for prevention of graft loss in pancreatic islet transplantation, but it is not approved or marketed in any EU member state.8 Material sold online as ARA-290 is an unregulated research chemical of unverified identity, purity and dose.11

For athletes the picture is unambiguous. The 2026 WADA Prohibited List bans, under S2.1 (erythropoietins and agents affecting erythropoiesis), both EPO-mimetic agents and an explicit category of innate repair receptor agonists.10 As an IRR agonist and EPO-derived peptide, cibinetide falls squarely within S2 and is prohibited at all times, both in and out of competition; being unapproved, it is additionally captured by S0 (non-approved substances), with no Therapeutic Use Exemption pathway.11 Any WADA-tested athlete should treat ARA-290 as banned.

Bottom line. ARA-290 is one of the more legitimately clinically-advanced non-hematopoietic EPO-analog peptides: a clean, well-defined mechanism plus real randomized, double-blind, placebo-controlled Phase 2 data in two indications, with objective evidence of small-nerve-fiber regeneration at 4 mg subcutaneous daily. That earns it Grade B. What is proven is narrow and provisional; what is hyped — cardiac, brain, wound-healing and longevity claims — rests on animal data only. Key uncertainties remain: no Phase 3, near-total reliance on a single research network, tiny samples, no long-term safety, and a dormant developer. Regulatory reality in 2026: not FDA-approved, EMA orphan but unapproved, WADA-prohibited, and sold only as an unregulated research chemical. A scientifically credible, mechanistically elegant Phase 2 asset whose human promise is genuine but unconfirmed — not an approved therapy. The 2026 WADA listing should be re-verified against the live list before any competition reliance.